 Intranasal inactivated influenza vaccines, IIVs, have shown promise as a protective tool against seasonal influenza, with studies indicating that they can induce mucosal immune response and protect against a broad spectrum of influenza virus strains. This article was authored by Corey Sonno, Akira Ainae, Tadaki Suzuki, and others.